|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
JANUARY 15, 2007
A Buyer For MedImmune?  The crowd prodding MedImmune (MEDI
) to put itself on the block is apt to get bigger--even though the seventh-largest U.S. biotech has rejected such a move. David Katz, president of Matrix Asset Advisors, which owns 1.8 million shares, has urged the board to sell to a strategic buyer, noting that MedImmune has "world-class products and intellectual property" whose value can best be marketed by a biggie such as Pfizer (PFE
), Merck (MRK
), GlaxoSmithKline, (GSK
) or Johnson & Johnson (JNJ
). Its products include FluMist, a nasal spray vaccine, and Synagis, an injectable antibody to treat respiratory infections in infants. "A number of the bigger stockholders agree with us," says Katz, who figures MedImmune, now trading at 33, is worth 45. Among analysts who share Katz's view is Geoffrey Porges of Sanford C. Bernstein, who says management and the board should "actively consider the sale of the company to a major pharmaceutical buyer that has the capital, expertise, and infrastructure to more effectively manage and commercialize the product portfolio." Based on its earnings potential, MedImmune's worth is in the mid-to-high 40s, says Porges. He sees earnings of 26 cents a share in 2006 and 88 cents in 2007, vs. a loss in 2005.Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2007, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version